QR Code

A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system

IntroductionSotorasib and adagrasib have been widely used for the non-small cell lung cancer (NSCLC) patients harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation. It's necessary to assess their safety profiles in the real-world population.MethodsA retrospective pharmacovigilanc...

Full description

Saved in:
Main Authors: Lisha Wu, Maosheng Xu, Xueqin Li, Dilinuer Aierken, Jinxiu Yu, Tao Qin
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2024-08-01
Series:Frontiers in Pharmacology
Subjects:
adverse events
FAERS
disproportionality analysis
pharmacovigilance
sotorasib
adagrasib
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1418469/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items